The expression landscape of JAK1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC
出版年份 2021 全文链接
标题
The expression landscape of JAK1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC
作者
关键词
-
出版物
BMC BIOINFORMATICS
Volume 22, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-09-29
DOI
10.1186/s12859-021-04379-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Gut Microbiome Modulates Response to Cancer Immunotherapy
- (2020) Md Abdul Wadud Khan et al. DIGESTIVE DISEASES AND SCIENCES
- Osteopontin accelerates the development and metastasis of bladder cancer via activating JAK1/STAT1 pathway
- (2020) Na Zhang et al. Genes & Genomics
- Overcoming genetically-based resistance mechanisms to PD-1 blockade
- (2020) Davis Y. Torrejon et al. Cancer Discovery
- Loss of JAK1 Drives Innate Immune Deficiency
- (2019) Agnieszka Witalisz-Siepracka et al. Frontiers in Immunology
- Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
- (2019) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Interferon signature in patients with STAT1 gain-of-function mutation is epigenetically determined
- (2019) Epp Kaleviste et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- TISIDB: an integrated repository portal for tumor-immune system interactions
- (2019) Beibei Ru et al. BIOINFORMATICS
- Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis.
- (2019) Ila J Datar et al. CLINICAL CANCER RESEARCH
- Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
- (2019) Sonja Althammer et al. Journal for ImmunoTherapy of Cancer
- HOXA10 deteriorates gastric cancer through activating JAK1/STAT3 signaling pathway
- (2019) Wenchao Chen et al. Cancer Management and Research
- JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression
- (2019) Julian Mohrherr et al. INTERNATIONAL JOURNAL OF CANCER
- Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
- (2019) Arsen Osipov et al. Journal for ImmunoTherapy of Cancer
- JAK1 as a prognostic marker and its correlation with immune infiltrates in breast cancer
- (2019) Bo Chen et al. Aging-US
- Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignancies
- (2019) Carlos A Castaneda et al. Biomarkers in Medicine
- Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy
- (2019) Xu Lei et al. CANCER LETTERS
- Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
- (2019) Luyao Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
- (2019) Caroline S. Jansen et al. NATURE
- Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
- (2018) Edit Porpaczy et al. BLOOD
- Interleukin-6 and Interferon-α Signaling via JAK1–STAT Differentially Regulate Oncolytic versus Cytoprotective Antiviral States
- (2018) Oded Danziger et al. Frontiers in Immunology
- Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
- (2018) Na Luo et al. OncoImmunology
- Radiotherapy induces responses of lung cancer to CTLA-4 blockade
- (2018) Silvia C. Formenti et al. NATURE MEDICINE
- Janus Kinase 1 Plays a Critical Role in Mammary Cancer Progression
- (2018) Barbara L. Wehde et al. Cell Reports
- Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis
- (2018) Kaikai Shen et al. Journal of Thoracic Disease
- Functional Heterogeneity of CD4+ Tumor-Infiltrating Lymphocytes With a Resident Memory Phenotype in NSCLC
- (2018) Anna E. Oja et al. Frontiers in Immunology
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion
- (2017) Lee A. Albacker et al. PLoS One
- miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients
- (2016) András Lánczky et al. BREAST CANCER RESEARCH AND TREATMENT
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma
- (2015) Xiaoguang Li et al. GUT
- JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
- (2015) M. Kleppe et al. Cancer Discovery
- Targeting JAK1/STAT3 Signaling Suppresses Tumor Progression and Metastasis in a Peritoneal Model of Human Ovarian Cancer
- (2014) W. Wen et al. MOLECULAR CANCER THERAPEUTICS
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- PrognoScan: a new database for meta-analysis of the prognostic value of genes
- (2009) Hideaki Mizuno et al. BMC Medical Genomics
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More